Osteoclasts contribute to early development of chronic inflammation by promoting dysregulated hematopoiesis and myeloid skewing
- Others:
- Laboratoire de PhysioMédecine Moléculaire (LP2M) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS) ; COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)
- University of Rochester Medical Center (URMC)
- Infection et inflammation (2I) ; Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Immunopathologie et chimie thérapeutique (ICT) ; Institut de biologie moléculaire et cellulaire (IBMC) ; Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)
- Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)
- Service d'Hépato-gastro-entérologie [CHRU Nancy] ; Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)
- Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA) ; Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)
Description
Increased myelopoiesis is a hallmark of many chronic inflammatory diseases. However, the mechanisms involved in the myeloid skewing of hematopoiesis upon inflammation are still incompletely understood. Here, we identify an unexpected role of bone-resorbing osteoclasts in promoting hematopoietic stem cell (HSC) proliferation and differentiation towards myeloipoiesis in the early phases of chronic colitis. RNAseq analysis revealed that osteoclasts in colitis differ from control ones and overexpress genes involved in the remodeling of HSC niches. We showed that colitic osteoclasts modulate the interaction of HSCs with their niche and promote myeloid differentiation. Increased osteoclast activity was correlated with an augmentation of myelopoiesis in patients with chronic colitis. Therapeutic blockade of osteoclasts reduced HSC proliferation and myeloid skewing and resulted in a decreased inflammation and severity of colitis. Together, these data identify osteoclasts as potent regulators of HSCs and promising target in chronic colitis.
Additional details
- URL
- https://hal.archives-ouvertes.fr/hal-03064977
- URN
- urn:oai:HAL:hal-03064977v1
- Origin repository
- UNICA